AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17846259 — intervention group
Group type: COMPARATOR
Intervention: Placebo pill
Number of subjects: 202
Study 15389191 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriasis Area and Severity Index (PASI)
Number of subjects: 35
Study 15389191 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriasis Global Assessment (PGA)
Number of subjects: 35
Study 15389191 — intervention group
Group type: EXPERIMENTAL
Intervention: Lattice System Physician's Global Assessment (LS-PGA)
Number of subjects: 35
Study 11476360 — intervention group
Group type: EXPERIMENTAL
Intervention: Lispro insulin (LP)
Number of subjects: 12
Study 11476360 — intervention group
Group type: COMPARATOR
Intervention: Regular insulin (HR)
Number of subjects: 12
Study 9836002 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (low dosage)
Number of subjects: 0
Study 9836002 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol (high pharmacologic dosage)
Number of subjects: 0
Study 7932128 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 mm incision (Group A)
Number of subjects: 107
Study 7932128 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5 mm incision (Group B)
Number of subjects: 107
Study 7932128 — intervention group
Group type: COMPARATOR
Intervention: Both groups (3.5 mm and 4.5 mm)
Number of subjects: 107
Study 2971504 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg dose of depot‐medroxyprogesterone acetate (DMPA)
Number of subjects: 0
Study 2971504 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg dose of depot‐medroxyprogesterone acetate (DMPA)
Number of subjects: 0
Study 2971504 — intervention group
Group type: COMPARATOR
Intervention: Reference period method of analysis
Number of subjects: 0
Study 31954191 — intervention group
Group type: EXPERIMENTAL
Intervention: Timothy grass SLIT-tablet
Number of subjects: 1818
Study 31954191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1818
Study 29459188 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 55
Study 29459188 — intervention group
Group type: COMPARATOR
Intervention: Catheterization
Number of subjects: 55
Study 29459188 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonographic evaluation of bladder volume
Number of subjects: 55
Study 27246303 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week physical activity intervention (behavioral counseling, physical activity, home-based walking)
Number of subjects: 40
Study 24631981 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger drivers
Number of subjects: 0
Study 24631981 — intervention group
Group type: EXPERIMENTAL
Intervention: Older drivers
Number of subjects: 0
Study 24631981 — intervention group
Group type: COMPARATOR
Intervention: Workload (variability of lead car speed)
Number of subjects: 0
Study 24631981 — intervention group
Group type: COMPARATOR
Intervention: Control experiment (constant projected size and position of targets)
Number of subjects: 0
Study 23541417 — intervention group
Group type: EXPERIMENTAL
Intervention: CC and rFSH (group B)
Number of subjects: 259
Study 23541417 — intervention group
Group type: COMPARATOR
Intervention: CC and hMG (group A)
Number of subjects: 259
Study 23541417 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 259
Study 20668943 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylalanine (Phe) loading test (100 mg/kg)
Number of subjects: 24
Study 18840367 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/Ramipril combination therapy (mean dose 7.60/7.60 mg)
Number of subjects: 222
Study 18840367 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine monotherapy (mean dose 7.97 mg)
Number of subjects: 222
Study 18840367 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/Ramipril combination therapy
Number of subjects: 222
Study 18840367 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine monotherapy
Number of subjects: 222
Study 16880243 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg) administered via a 15-minute infusion every 3 or 4 weeks for 12 infusions
Number of subjects: 312
Study 16880243 — intervention group
Group type: COMPARATOR
Intervention: Placebo (implied control from randomized phase III trials)
Number of subjects: 312
Study 12818279 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 mg NT‐3 three times per week (TTW)
Number of subjects: 107
Study 12818279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 15612515 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride (up to 4 mg)
Number of subjects: 104
Study 15612515 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2 g)
Number of subjects: 104
Study 15612515 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (4 mg glimepiride plus 2 g metformin)
Number of subjects: 104
Study 9971866 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine plus triiodothyronine (12.5 microg of triiodothyronine replacing 50 microg of thyroxine)
Number of subjects: 33
Study 9971866 — intervention group
Group type: COMPARATOR
Intervention: Thyroxine alone (usual dose)
Number of subjects: 33
Study 7750591 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (10 mg/d)
Number of subjects: 11
Study 7750591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 2180642 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection of the cremaster muscle
Number of subjects: 390
Study 2180642 — intervention group
Group type: COMPARATOR
Intervention: No resection of the cremaster muscle
Number of subjects: 390
Study 7009858 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 0
Study 7009858 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 0
Study 7009858 — intervention group
Group type: EXPERIMENTAL
Intervention: Salicylates
Number of subjects: 0
Study 7009858 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 0
Study 7009858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31924539 — intervention group
Group type: EXPERIMENTAL
Intervention: Zvandiri intervention group (peer-led differentiated service delivery model)
Number of subjects: 496
Study 31924539 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard HIV care)
Number of subjects: 496
Study 31924539 — intervention group
Group type: EXPERIMENTAL
Intervention: Zvandiri intervention group
Number of subjects: 496
Study 31924539 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 496
Study 28060083 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity lifestyle intervention program (group sessions, individual counseling, telephone follow-ups over 3 months)
Number of subjects: 183
Study 28060083 — intervention group
Group type: COMPARATOR
Intervention: Standard care plus attention placebo (control group)
Number of subjects: 183
Study 25816110 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan/Hydrochlorothiazide (Los/HCTZ)
Number of subjects: 110
Study 25816110 — intervention group
Group type: COMPARATOR
Intervention: High-dose Losartan (High-Los)
Number of subjects: 110
Study 23511349 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane SEALGUARD Evac® endotracheal tube
Number of subjects: 29
Study 23511349 — intervention group
Group type: COMPARATOR
Intervention: Polyvinyl HI-LO Evac® endotracheal tube
Number of subjects: 29
Study 23511349 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger tubes (size 9)
Number of subjects: 29
Study 21837956 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral plasmakinetic enucleation of the prostate (PKEP)
Number of subjects: 90
Study 21837956 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 90
Study 19652995 — intervention group
Group type: EXPERIMENTAL
Intervention: Local cold-pack application
Number of subjects: 12
Study 19652995 — intervention group
Group type: COMPARATOR
Intervention: Sprint-interval training without cold-pack application
Number of subjects: 12
Study 17454421 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 15517668 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release oxybutynin chloride 10 mg (qd)
Number of subjects: 315
Study 15517668 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine tartrate 4 mg (2 mg bid)
Number of subjects: 315
Study 11432109 — intervention group
Group type: COMPARATOR
Intervention: u-FSH (150 IU/d)
Number of subjects: 88
Study 11432109 — intervention group
Group type: EXPERIMENTAL
Intervention: follitropin-alpha (100 IU/d)
Number of subjects: 88
Study 11432109 — intervention group
Group type: EXPERIMENTAL
Intervention: follitropin-beta (100 IU/d)
Number of subjects: 88
Study 11432109 — intervention group
Group type: EXPERIMENTAL
Intervention: r-FSH
Number of subjects: 88
Study 11432109 — intervention group
Group type: COMPARATOR
Intervention: u-FSH
Number of subjects: 88
Study 9018831 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent cooling
Number of subjects: 5
Study 9018831 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous cooling during intermittent exercise
Number of subjects: 5
Study 9018831 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient air cooling during continuous exercise
Number of subjects: 5
Study 9018831 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous air-cooling trial
Number of subjects: 5
Study 9018831 — intervention group
Group type: COMPARATOR
Intervention: No cooling (control)
Number of subjects: 5
Study 7942228 — intervention group
Group type: EXPERIMENTAL
Intervention: Vesical lavage cytology (LC)
Number of subjects: 171
Study 7942228 — intervention group
Group type: COMPARATOR
Intervention: Mictional cytology (MC)
Number of subjects: 171
Study 2967624 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygenated Fluosol DA, 20% emulsion (FDA-20)
Number of subjects: 42
Study 2967624 — intervention group
Group type: COMPARATOR
Intervention: Control solutions of oxygenated Ringer's lactate and nonoxygenated FDA-20
Number of subjects: 42
Study 2967624 — intervention group
Group type: COMPARATOR
Intervention: Nonperfused sequences
Number of subjects: 42
Study 31684923 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal care (ANC) attendance
Number of subjects: 3784
Study 31684923 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated net (ITN) ownership and use
Number of subjects: 3784
Study 31684923 — intervention group
Group type: COMPARATOR
Intervention: ANC attendance
Number of subjects: 3784
Study 31684923 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria infection prevalence
Number of subjects: 3784
Study 28947458 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT A (16 min interval training with 4, 2 and 1 min intervals at 80%-90% of peak oxygen uptake)
Number of subjects: 0
Study 28947458 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT B (4x4 min interval training at 80%-90% VO2peak)
Number of subjects: 0
Study 28947458 — intervention group
Group type: EXPERIMENTAL
Intervention: MICT (40 min cycling at 50%-60% VO2peak)
Number of subjects: 0
Study 25865864 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised falls-prevention education for patients, supported by training and feedback for staff, delivered as a ward-level programme.
Number of subjects: 3606
Study 23466918 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% aqueous chlorhexidine gluconate (CHG)
Number of subjects: 0
Study 23466918 — intervention group
Group type: COMPARATOR
Intervention: 10% povidone-iodine (PI)
Number of subjects: 0
Study 21875911 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep hypothermia with total circulatory arrest
Number of subjects: 139
Study 21875911 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous low-flow cardiopulmonary bypass
Number of subjects: 139
Study 21875911 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative seizures
Number of subjects: 139
Study 21875911 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging abnormalities in d-transposition of the great arteries group
Number of subjects: 139
Study 21875911 — intervention group
Group type: EXPERIMENTAL
Intervention: Remedial academic or behavioral services
Number of subjects: 139
Study 20027369 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoten
Number of subjects: 0
Study 17964396 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate 1% (Healon)
Number of subjects: 54
Study 17964396 — intervention group
Group type: COMPARATOR
Intervention: Chondroitin sulfate 4%-sodium hyaluronate 3% (Viscoat) in combination with sodium hyaluronate 1% (Provisc)
Number of subjects: 54
Study 15140340 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone buccal system (Striant), 30 mg twice daily
Number of subjects: 28
Study 15140340 — intervention group
Group type: COMPARATOR
Intervention: Transdermal gel delivery system (T‐gel), AndroGel 5 g containing 1% (50 mg) T, daily for 14 days
Number of subjects: 28
Study 15140340 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone buccal system
Number of subjects: 28
Study 15140340 — intervention group
Group type: COMPARATOR
Intervention: Transdermal gel delivery system (T‐gel)
Number of subjects: 28
Study 11943637 — intervention group
Group type: EXPERIMENTAL
Intervention: Red palm oil (RPO) consumption
Number of subjects: 210
Study 9419168 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy
Number of subjects: 1330
Study 7649646 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT)
Number of subjects: 0
Study 7649646 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment from an inactive machine
Number of subjects: 0
Study 2502843 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprenyl (10 mg/day)
Number of subjects: 54
Study 2502843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 329943 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol
Number of subjects: 3053
Study 329943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3053
Study 30552041 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (7 mg dermal patch)
Number of subjects: 26
Study 30552041 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (60 mg per os)
Number of subjects: 26
Study 30552041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 27146248 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of lipid-based nutrient supplements plus malaria and diarrhoea treatment from age 9 to 18 months
Number of subjects: 0
Study 27146248 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of lipid-based nutrient supplements plus malaria and diarrhoea treatment
Number of subjects: 0
Study 26088659 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant monotherapy
Number of subjects: 206
Study 26088659 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine alone or with a stimulant
Number of subjects: 206
Study 26088659 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic usually together with a stimulant
Number of subjects: 206
Study 26088659 — intervention group
Group type: EXPERIMENTAL
Intervention: Other pharmacotherapy
Number of subjects: 206
Study 26088659 — intervention group
Group type: EXPERIMENTAL
Intervention: Indicated ADHD medication
Number of subjects: 206
Study 26088659 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic
Number of subjects: 206
Study 26088659 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment
Number of subjects: 206
Study 26088659 — intervention group
Group type: EXPERIMENTAL
Intervention: No pharmacotherapy
Number of subjects: 206
Study 23782741 — intervention group
Group type: EXPERIMENTAL
Intervention: SystemCHANGE™ intervention
Number of subjects: 35
Study 23782741 — intervention group
Group type: COMPARATOR
Intervention: Contact-control intervention
Number of subjects: 35
Study 22188761 — intervention group
Group type: EXPERIMENTAL
Intervention: ARA-enriched oil (240 or 720 mg ARA per day)
Number of subjects: 0
Study 22188761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19395188 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy (EBRT) plus androgen deprivation therapy
Number of subjects: 284
Study 19395188 — intervention group
Group type: COMPARATOR
Intervention: Radical prostatectomy (RP)
Number of subjects: 284
Study 16234828 — intervention group
Group type: EXPERIMENTAL
Intervention: Low GI/high DF bread
Number of subjects: 7
Study 16234828 — intervention group
Group type: COMPARATOR
Intervention: High GI/low DF bread
Number of subjects: 7
Study 15256239 — intervention group
Group type: EXPERIMENTAL
Intervention: FAMTX (5-Fluorouracil, doxorubicin, methotrexate)
Number of subjects: 59
Study 15256239 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 59
Study 10905544 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily fish meals
Number of subjects: 0
Study 10905544 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA, 20:5 omega3) or docosahexaenoic acid (DHA, 22:6 omega3)
Number of subjects: 0
Study 10168173 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 0
Study 10168173 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study 8163889 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% hydrocortisone and 1.0% lignocaine hydrochloride no-touch aqueous spray
Number of subjects: 83
Study 3098573 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritanserin (serotonin-S2 antagonist), administered for five days
Number of subjects: 0
Study 3098573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31304380 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaia App (multidisciplinary mHealth back pain App) for 3 months
Number of subjects: 101
Study 31304380 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (six individual physiotherapy sessions over 6 weeks and high-quality online education)
Number of subjects: 101
Study 29924421 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo exposure group treatment
Number of subjects: 43
Study 27054681 — intervention group
Group type: EXPERIMENTAL
Intervention: RTI (Resistance Training with Instability)
Number of subjects: 39
Study 27054681 — intervention group
Group type: EXPERIMENTAL
Intervention: RT (Resistance Training)
Number of subjects: 39
Study 27054681 — intervention group
Group type: COMPARATOR
Intervention: C (Control group)
Number of subjects: 39
Study 27054681 — intervention group
Group type: EXPERIMENTAL
Intervention: RTI
Number of subjects: 39
Study 25493974 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous progesterone
Number of subjects: 882
Study 25493974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 882
Study 22761453 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 1521
Study 22761453 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 1521
Study 20104528 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (ascorbic acid 120 mg, vitamin E 30 mg, beta‐carotene 6 mg, selenium 100 microg, zinc 20 mg)
Number of subjects: 12741
Study 20104528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12741
Study 18469433 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-delivered contraceptives in the home
Number of subjects: 103
Study 18469433 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (not specified intervention)
Number of subjects: 103
Study 18469433 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment activities
Number of subjects: 103
Study 18469433 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention activities
Number of subjects: 103
Study 15272923 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (180 mg/day orally) plus oestradiol (100 microg/24 h) from days 21 to 30 (R‐Exp)
Number of subjects: 16
Study 15272923 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene (150 mg/day orally) plus oestradiol (100 microg/24 h) from days 21 to 30 (Cl‐Exp)
Number of subjects: 16
Study 15272923 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 treatment in Group 2 (30 days) plus R from days 21 to 30 (R‐Exp)
Number of subjects: 16
Study 15272923 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 treatment in Group 2 (30 days) plus Cl from days 21 to 30 (Cl‐Exp)
Number of subjects: 16
Study 15272923 — intervention group
Group type: COMPARATOR
Intervention: Cl addition (for 10 days) in Group 2
Number of subjects: 16
Study 15272923 — intervention group
Group type: EXPERIMENTAL
Intervention: R addition in Group 2
Number of subjects: 16
Study 11434469 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-power laser (LPL) therapy
Number of subjects: 60
Study 11434469 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser
Number of subjects: 60
Study 9605676 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral head position
Number of subjects: 18
Study 9605676 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended head position
Number of subjects: 18
Study 9605676 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexed head position
Number of subjects: 18
Study 9605676 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific intervention)
Number of subjects: 18
Study 7817728 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers experiencing stillbirth
Number of subjects: 210
Study 7817728 — intervention group
Group type: COMPARATOR
Intervention: Control mothers
Number of subjects: 210
Study 2898052 — intervention group
Group type: EXPERIMENTAL
Intervention: B subunit killed whole-cell (BS-WC) vaccine
Number of subjects: 62285
Study 2898052 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed whole-cell-only (WC) vaccine
Number of subjects: 62285
Study 2898052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62285
Study 1199703 — intervention group
Group type: EXPERIMENTAL
Intervention: Human chorionic somatomammotropin (S HCS) concentration measured by radioimmunoassay
Number of subjects: 393
Study 1199703 — intervention group
Group type: EXPERIMENTAL
Intervention: S HCS concentration
Number of subjects: 393
Study 31721407 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubeless PCNL (JJ stent only)
Number of subjects: 75
Study 31721407 — intervention group
Group type: COMPARATOR
Intervention: Standard PCNL (nephrostomy tube and JJ stent)
Number of subjects: 75